Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’ – A New Category in Genetic Medicine

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2LpwEwE
via IFTTT